Year: 2012
Type: dissertation
Abstract: Hepatocellular carcinoma (HCC) as a, heterogeneous, multi-step, slowprogressing disease, has very limited treatment options due to its chemoresistant nature and late diagnosis.According to World Health Organization (WHO) reports HCC is a major public health problem.Each year, 748,000 new cases appear and 696,000 people lose their lives, all due to liver cancer alone.Sorafenib, the multi-tyrosine kinase inhibitor, is still the only (Food and Drug Administration) FDA-approved drug available for treatment.Therefore, there is an urgent need for novel, target-specific drugs based on the underlying molecular mechanisms of liver carcinogenesis.In this Ph.D. dissertation, synthetic purine, purine nucleoside analogs, aminotriazole and thiadiazine derivatives were evaluated for their cytotoxic activities and mechanisms of action against liver cancer.These novel molecules were selected because of their potential kinase inhibitory activity.Protein kinases, involved in signaling pathways, are the main enzymes of target-specific drug discovery; therefore, discovery of novel, putative protein kinase inhibitors as drug candidates can be promising for the treatment of primary liver cancer.Initially, sulforhodamine B (SRB) assay was used to screen the novel smallmolecules for their cytotoxic activities against breast, colon and liver cancer cell lines.Active molecules, then, were further exploited on a panel of HCC cell lines.The differential IC50 (half-maximal inhibitory concentration) values obtained, might indicate that these small-molecules interfere with cell signaling; since, these This work was supported
Author: Güven, Ebru Bilget
Institution: Ankara University
Language: English
Subfield: Organic Chemistry
Field: Chemistry
Domain: Physical Sciences
Open Access status: green
OpenAlex ID: W7038395155
